From - Laboratory Industry Report
One quarter into its existence, the new PAMA Medicare Part B fee schedule seems to be having only a marginal impact on at least publicly traded labs…
From - National Intelligence Report
One quarter into its existence, the new PAMA Medicare Part B fee schedule seems to be having only a marginal impact on at least publicly traded labs. In fact, the recently published…
From - Laboratory Industry Report
Big PAMA cuts may lay ahead in 2017, but the diagnostics industry had a robust 2017. While the entire year was strong, success was…
